Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158079 · ClinicalTrials.gov registry record · Phase 1
Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment
A Phase 1 study, sponsored by Alnylam Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT01158079: Completed Phase 1 study, sponsored by Alnylam Pharmaceuticals.
NCT01158079 is a Phase 1 study that has completed, run by Alnylam Pharmaceuticals. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01158079, a Phase 1 study, has completed, sponsored by Alnylam Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study provides a mechanism for continued administration of ALN-VSP02 therapy to patients with cancer who completed participation in another ALN-VSP02 clinical study. The primary objective of this study is to collect long term safety data.
Primary Outcome
Patients remain on treatment until disease progression or an adverse event. Adverse events are assessed throughout treatment.
Interventions
- DRUG ALN-VSP02
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
What the finished NCT01158079 record still lists
NCT01158079 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which ALN-VSP02 is the first listed.
NCT01158079 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01158079 about?
NCT01158079 is a clinical study titled "Multi-center, Open Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment". This study provides a mechanism for continued administration of ALN-VSP02 therapy to patients with cancer who completed participation in another ALN-VSP02 clinical study. The primary objective of this study is to collect long term safety data.
What is the current status of trial NCT01158079?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2010-07. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01158079?
The interventions under investigation include: ALN-VSP02 (DRUG).
Who is sponsoring clinical trial NCT01158079?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01158079's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia